Theravance Uses Organ-Selective R&D To Advance GI, Pulmonary Candidates
Executive Summary
Company develops selective JAK inhibitors for IBD and pulmonary disease that are intended to clear the body before systemic side effects can occur. It also has a drug candidate for NOH that analysts think is underappreciated.